Axellis
Entry
2018
Hold
4yr
Exit
2022
Who owns Axellis?
Axellis was owned by Sobera Capital through Sobera Capital Fund IV (2017 vintage) from 2018 to 2022.
Hand-verified · updated 2026-08-10
Exit Type
–
Buyer
–
MOIC
–
Exit Year
2022
More from Sobera Capital Fund IV
Other portfolio companies in the same fund.
EffRx Pharmaceuticals
Exited 2023
Pharma
Switzerland· 2018
Switzerland· 2018to
M.O.R.E Medical Solutions
Active
MedTech
Germany· 2018
Germany· 2018
Memo Therapeutics
Exited 2026
BiotechSwitzerland· 2018
Switzerland· 2018to
MyoScience
Exited 2019
MedTech
United States· 2018
United States· 2018to
Presidio Pharmaceuticals
Active
PharmaUnited States· 2018
United States· 2018Panoratio
Exited 2021
Data & AnalyticsGermany· 2015
Germany· 2015More PE-backed in MedTech
Comparable medtech deals from other GPs.
Optos
Exited 2015
Amadeus Capital Partners
UK
UKto
Axomove
Active
Go Capital
France· 2026
France· 2026Bioliberty
Active
Scottish National Investment BankUK· 2026
UK· 2026CertHub
Active
Cusp Capital PartnersGermany· 2026
Germany· 2026Clee Medical
Active
High-Tech Gruenderfonds (HTGF)Switzerland· 2026
Switzerland· 2026CollimateHealth
Active
Caesar Ventures ManagementGermany· 2026
Germany· 2026Track Axellis
Save this record to your watchlist and pick up your research where you left off. No spam.
Get the full record on Axellis.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
Already a member? Sign in
Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue